Roche’s Alecensa Delivers Unprecedented Phase III Results for People with ALK-Positive Early-Stage Lung Cancer

Roche announced today that the Phase III ALINA study evaluating Alecensa® met its primary endpoint of disease-free survival at a prespecified interim analysis. Alecensa is the first ALK inhibitor to demonstrate a reduction in the risk of disease recurrence or death for people with early-stage ALK-positive NSCLC in a Phase III trial.